newsfilter
← Latest News
GlobeNewswire·

AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets

ATAI
  • AtaiBeckley Inc. (NASDAQ: ATAI) will be added to the Russell 2000® and Russell 3000® Indexes effective at the market open on June 29, 2026, as part of the first 2026 reconstitution.
  • Approximately $12.2 trillion in assets are benchmarked against the Russell U.S. Indexes, which serve as a key reference system for institutional investors and funds.
  • The Russell 2000® Index tracks roughly 2,000 small-cap U.S. equities, while the Russell 3000® Index covers about 3,000 stocks representing approximately 98% of investable U.S. equities by market capitalization.
  • FTSE Russell determines index membership based primarily on objective market-capitalization rankings & style attributes.
  • Srinivas Rao, Co-Founder & CEO, stated that the inclusion marks a milestone for expanding visibility with institutional investors as the company advances its Phase 3 study of BPL-003.
  • This addition follows AtaiBeckley's recent inclusion in the S&P Total Market Index, S&P Completion Index, & CRSP® U.S. benchmark indexes in March 2026.
  • AtaiBeckley is a clinical-stage biotechnology company developing mental health treatments, with BPL-003 in Phase 3 development for treatment-resistant depression (TRD) after receiving Breakthrough Therapy Designation.
  • The company's pipeline also includes VLS-01 & EMP-01 in Phase 2 development for TRD & social anxiety disorder, respectively.
  • AtaiBeckley is advancing a drug discovery program to identify non-hallucinogenic 5-HT2AR agonists for opioid use disorder & TRD.
  • The press release includes standard forward-looking statement disclaimers regarding risks, uncertainties, & potential differences between projected & actual results.